

CITATION REPORT

List of articles citing

Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment

DOI: 10.1097/00045391-200501000-00005

American Journal of Therapeutics, 2005, 12, 22-34.

Source: <https://exaly.com/paper-pdf/37979846/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
134	Correction of allopurinol dosing should be based on clearance of creatinine, but not plasma creatinine levels: another insight to allopurinol-related toxicity. 2005 , 11, 129-33		38
133	Febuxostat: a non-purine, selective inhibitor of xanthine oxidase for the management of hyperuricaemia in patients with gout. 2005 , 14, 893-903		36
132	Febuxostat compared with allopurinol in patients with hyperuricemia and gout. 2005 , 353, 2450-61		891
131	Febuxostat--treatment for hyperuricemia and gout?. 2005 , 353, 2505-7		13
130	Clinical trials in crystal arthropathy. 2006 , 32, 359-82, vii		3
129	Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects. 2006 , 45, 821-41		70
128	Pathophysiology, clinical presentation and treatment of gout. 2006 , 66, 1547-63		42
127	Febuxostat: a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout. 2006 , 40, 2187-94		44
126	The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. 2006 , 46, 88-102		59
125	Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. 2006 , 58, 87-114		819
124	Febuxostat: A Novel, Non-Purine Xanthine Oxidase Inhibitor. 2006 , 22, 342-348		1
123	Febuxostat: a safe and effective therapy for hyperuricemia and gout. 2006 , 1, 303-309		
122	Crystal-induced arthropathies: recent investigative advances. 2006 , 18, 249-55		12
121	Quantification of uric acid, xanthine and hypoxanthine in human serum by HPLC for pharmacodynamic studies. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2006 , 837, 1-10	3.2	133
120	Pharmacokinetic interactions of concomitant administration of febuxostat and NSAIDs. 2006 , 46, 855-66		35
119	Tumor lysis syndrome. 2007 , 33, 397-407		40
118	Febuxostat: a novel non-purine selective inhibitor of xanthine oxidase for the treatment of hyperuricemia in gout. 2007 , 1, 69-75		38

117	Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout. 2007 , 4, 83-93		79
116	Traitement de la goutte. 2007 , 74, 160-167		12
115	Emerging therapies in the long-term management of hyperuricaemia and gout. 2007 , 37, 258-66		40
114	Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. 2008 , 59, 1540-8		429
113	Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2008 , 65, 355-63	3.8	56
112	Management of hyperuricemia and gout in CKD. 2008 , 52, 994-1009		19
111	Febuxostat. 2008 , 68, 1865-74		25
110	The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. 2008 , 48, 1014-24		36
109	In vitro drug-drug interaction studies with febuxostat, a novel non-purine selective inhibitor of xanthine oxidase: plasma protein binding, identification of metabolic enzymes and cytochrome P450 inhibition. 2008 , 38, 496-510		46
108	Febuxostat, a novel drug for the treatment of hyperuricemia of gout. 2008 , 3, 421-427		5
107	Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. 2009 , 48, 188-94		181
106	Febuxostat in the management of hyperuricemia and chronic gout: a review. 2008 , 4, 1209-20		26
105	Febuxostat: a new treatment for hyperuricaemia in gout. 2009 , 48 Suppl 2, ii15-ii19		57
104	Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout. 2009 , 31, 2503-18		58
103	Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. 2009 , 36, 1273-82		197
102	Gout: new advances in the diagnosis and management of an old disease. 2009 , 4, 203-220		6
101	Update on emerging urate-lowering therapies. 2009 , 21, 143-9		37
100	Advances and unmet needs in gout. 2010 , 5, 187-197		

99	Urate-lowering therapy for gout: focus on febuxostat. 2010 , 30, 594-608		64
98	Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of febuxostat, a non-purine selective inhibitor of xanthine oxidase. <i>British Journal of Clinical Pharmacology</i> , 2010 , 70, 57-64	3.8	16
97	Advances in the management of gout: critical appraisal of febuxostat in the control of hyperuricemia. 2010 , 3, 1-10		9
96	Management of hyperuricemia in gout: focus on febuxostat. 2010 , 5, 7-18		35
95	Gout therapeutics: new drugs for an old disease. 2011 , 377, 165-77		154
94	A new standard of care? Studies on febuxostat in the management of hyperuricemia with and without gout. 2011 , 17, S11-2		
93	Evaluation and management of nephrolithiasis in the aging population with chronic kidney disease. 2011 , 7, 423-433		1
92	Comorbidities in Gouty Arthritis. 2011 , 59, 1211-1220		8
91	Medical therapy for calculus disease. 2011 , 107, 356-68		23
90	Febuxostat for treatment of chronic gout. 2011 , 68, 389-98		27
89	Effect of acute xanthine oxidase inhibition on myocardial energetics during basal and very high cardiac workstates. 2011 , 4, 504-13		5
88	Febuxostat. 2011 , 6, 524-528		
87	Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. 2011 , 63, 412-21		165
86	2011 Recommendations for the diagnosis and management of gout and hyperuricemia. 2011 , 123, 3-36		80
85	2011 recommendations for the diagnosis and management of gout and hyperuricemia. 2011 , 39, 98-123		31
84	Potential pharmacologic treatments for cystinuria and for calcium stones associated with hyperuricosuria. 2011 , 6, 2093-7		20
83	Efficacy and safety of febuxostat in patients with hyperuricemia and gout. 2011 , 3, 245-53		25
82	Management of Chronic Hyperuricemia with Febuxostat. 2011 , 3, 287-297		

81	Pharmacokinetics of febuxostat in healthy Chinese volunteers. 2012 , 62, 463-9	6
80	Hypouricemic effect of the methanol extract from Prunus mume fruit in mice. 2012 , 50, 1423-7	13
79	Perspectives des uricases dans la goutte. 2012 , 79, 17-22	3
78	Ultrahigh performance liquid chromatography-triple quadrupole mass spectrometry inhibitors fishing assay: a novel method for simultaneously screening of xanthine oxidase inhibitor and superoxide anion scavenger in a single analysis. 2012 , 715, 64-70	44
77	A New-Generation Uric Acid Production Inhibitor: Febuxostat. 2012 , 365-376	
76	Xanthine Oxidase Inhibitor Treatment of Hyperuricemia. 2012 , 154-173	1
75	Therapeutic perspectives on uricases for gout. 2012 , 79, 237-42	35
74	Determination of febuxostat in human plasma using ultra-performance liquid chromatography tandem mass spectrometry. 2013 , 5, 492-9	24
73	Acute neutropenia associated with initiation of febuxostat therapy for hyperuricaemia in patients with chronic kidney disease. 2013 , 38, 258-61	13
72	Efficacy and tolerability of febuxostat in hyperuricemic patients with or without gout: a systematic review and meta-analysis. 2013 , 35, 180-9	37
71	Management of Hyperuricemia and Gout. 2013 , 291-385	
70	Febuxostat: a new drug for an old disease. Do we really need it?. 2013 , 103-106	
69	Successful treatment of refractory gout using combined therapy consisting of febuxostat and allopurinol in a patient with chronic renal failure. 2014 , 53, 609-12	9
68	Rhabdomyolysis associated with initiation of febuxostat therapy for hyperuricaemia in a patient with chronic kidney disease. 2014 , 39, 328-30	15
67	Pharmacokinetics considerations for gout treatments. 2014 , 10, 949-57	10
66	Hypouricemic effect and safety of febuxostat used for prevention of tumor lysis syndrome. 2014 , 3, 501	9
65	Method Development and Validation for Determination of Febuxostat from Spiked Human Plasma Using RP-HPLC with UV Detection. 2014 , 2014, 1-5	11
64	Management of gouty arthritis in patients with chronic kidney disease. <i>American Journal of Therapeutics</i> , 2014 , 21, 523-34	1 11

63	Are there concerns about generic medicines in rheumatology?. 2014 , 81, 1-3	
62	Efficacy and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase for the treatment of hyperuricemia in kidney transplant recipients. 2014 , 46, 511-3	16
61	Acute severe liver dysfunction induced by febuxostat in a patient undergoing hemodialysis. 2014 , 3, 158-161	9
60	The effect of febuxostat to prevent a further reduction in renal function of patients with hyperuricemia who have never had gout and are complicated by chronic kidney disease stage 3: study protocol for a multicenter randomized controlled study. 2014 , 15, 26	52
59	Les médicaments génériques posent-ils un problème en rhumatologie?. 2014 , 81, 1-3	
58	Febuxostat: drug review and update. 2014 , 10, 747-58	21
57	Therapeutic approaches to chronic hyperuricemia and gout. 2014 , 21, 243-50	17
56	Switching from allopurinol to febuxostat: efficacy and tolerability in hemodialysis patients. 2015 , 1, 28	4
55	Febuxostat: a review of its use in the treatment of hyperuricaemia in patients with gout. 2015 , 75, 427-38	44
54	Simultaneous determination of febuxostat and its three active metabolites in human plasma by liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study in Chinese healthy volunteers. 2015 , 114, 216-21	20
53	Population Pharmacokinetics and Therapeutic Efficacy of Febuxostat in Patients with Severe Renal Impairment. 2015 , 96, 90-8	26
52	Impact of Febuxostat on Renal Function in Gout Patients With Moderate-to-Severe Renal Impairment. 2016 , 68, 2035-43	69
51	Febuxostat for Patients With Gout and Severe Chronic Kidney Disease: Which Is the Appropriate Dosage? Comment on the Article by Saag et al. 2016 , 68, 2563-4	8
50	Modeling and Simulation for Estimating the Influence of Renal Dysfunction on the Hypouricemic Effect of Febuxostat in Hyperuricemic Patients Due to Overproduction or Underexcretion of Uric Acid. <i>Biological and Pharmaceutical Bulletin</i> , 2016 , 39, 1013-21	2.3 2
49	Comparison of topiroxostat and allopurinol in Japanese hyperuricemic patients with or without gout: a phase 3, multicentre, randomized, double-blind, double-dummy, active-controlled, parallel-group study. 2016 , 41, 290-7	33
48	Clinical efficacy and safety of topiroxostat in Japanese male hyperuricemic patients with or without gout: an exploratory, phase 2a, multicentre, randomized, double-blind, placebo-controlled study. 2016 , 41, 298-305	18
47	Xanthine oxidoreductase and its inhibitors: relevance for gout. 2016 , 130, 2167-2180	21
46	Effects, safety, and plasma levels of topiroxostat and its metabolites in patients receiving hemodialysis. 2016 , 2,	3

45	Febuxostat for the chronic management of hyperuricemia in patients with gout. 2016 , 9, 665-73		19
44	Gout: optimizing treatment to achieve a disease cure. 2016 , 7, 135-44		22
43	Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome and the Rheumatologist. 2017 , 19, 3		18
42	Effect of Febuxostat on the Endothelial Dysfunction in Hemodialysis Patients: A Randomized, Placebo-Controlled, Double-Blinded Study. 2017 , 45, 452-459		17
41	Reply to comments from Vincent et al. 2017 , 22, 607-608		
40	Identification of chronic kidney disease patient characteristics influencing the renoprotective effects of febuxostat therapy: a retrospective follow-up study. 2017 , 18, 162		10
39	Lemon fruits lower the blood uric acid levels in humans and mice. 2017 , 220, 4-10		10
38	Emergencies in Hematology and Oncology. 2017 , 92, 609-641		19
37	The Effect of Xanthine Oxidase Inhibitors on Blood Pressure and Renal Function. 2017 , 19, 95		33
36	Clinical Pharmacokinetics and Pharmacodynamics of Febuxostat. 2017 , 56, 459-475		20
35	Effects of UDP-glucuronosyltransferase (UGT) polymorphisms on the pharmacokinetics of febuxostat in healthy Chinese volunteers. 2017 , 32, 77-84		11
34	[Analysis of the 2015 British guidelines on the prevention and management of tumor lysis syndrome]. <i>Revue De Medecine Interne</i> , 2017 , 38, 36-43	0.1	3
33	Prevention and treatment of tumor lysis syndrome, and the efficacy and role of rasburicase. <i>OncoTargets and Therapy</i> , 2017 , 10, 597-605	4.4	48
32	Comparison of Clinical Advantage between Topiroxostat and Febuxostat in Hemodialysis Patients. <i>Biological and Pharmaceutical Bulletin</i> , 2017 , 40, 1463-1467	2.3	7
31	Urate-Lowering Therapy. 2017 , 1061-1074.e3		2
30	The impact of serum uric acid reduction on renal function and blood pressure in chronic kidney disease patients with hyperuricemia. <i>Clinical and Experimental Nephrology</i> , 2018 , 22, 1300-1308	2.5	14
29	Design and Rationale for the Veterans Affairs "Cooperative Study Program 594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat" Trial. <i>Contemporary Clinical Trials</i> , 2018 , 68, 102-108	2.3	7
28	Process Development of Febuxostat Using Palladium- and Copper-Catalyzed C-H Arylation. <i>Organic Process Research and Development</i> , 2018 , 22, 1306-1311	3.9	8

27	Side Effects and Interactions of the Xanthine Oxidase Inhibitor Febuxostat. <i>Pharmaceuticals</i> , 2018 , 11,	5.2	29
26	Febuxostat for the treatment of hyperuricaemia in gout. <i>Expert Opinion on Pharmacotherapy</i> , 2018 , 19, 1289-1299	4	14
25	Risk-based management strategy and outcomes of tumor lysis syndrome in children with leukemia/lymphoma: Analysis from a resource-limited setting. <i>Pediatric Blood and Cancer</i> , 2018 , 65, e27401	2.8	6
24	Evaluation of a pharmacokinetic-pharmacodynamic model for hypouricaemic effects of febuxostat using datasets obtained from real-world patients. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 2260-2269	2.8	2
23	Tumor Lysis Syndrome: A Practical Guide for Nurse Practitioners. <i>Journal for Nurse Practitioners</i> , 2019 , 15, 636-639	0.6	1
22	Determination of febuxostat in human plasma by high performance liquid chromatography (HPLC) with fluorescence-detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2019 , 1126-1127, 121764	3.2	5
21	Pharmacological urate-lowering approaches in chronic kidney disease. <i>European Journal of Medicinal Chemistry</i> , 2019 , 166, 186-196	6.8	11
20	In silico design and synthesis of targeted rutin derivatives as xanthine oxidase inhibitors. <i>BMC Chemistry</i> , 2019 , 13, 71	3.7	5
19	Gout Management in Chronic Kidney Disease: Pearls and Pitfalls. <i>Current Treatment Options in Rheumatology</i> , 2019 , 5, 326-335	1.3	
18	Diagnosis and management of tumor lysis syndrome. <i>Journal of Community Hospital Internal Medicine Perspectives</i> , 2020 , 10, 269-272	1.1	4
17	A pharmacokinetic-pharmacodynamic study of a single dose of febuxostat in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2020 , 86, 2486-2496	3.8	2
16	Simultaneous determination of colchicine and febuxostat in rat plasma: Application in a rat pharmacokinetic study. <i>Biomedical Chromatography</i> , 2020 , 34, e4939	1.7	6
15	A sensitive HPLC-FL method to simultaneously determine febuxostat and diclofenac in rat plasma: assessment of metabolic drug interactions in vitro and in vivo. <i>Analytical Methods</i> , 2020 , 12, 2166-2175	3.2	10
14	Comparison of efficacy and safety of urate-lowering therapies for hyperuricemic patients with gout: a meta-analysis of randomized, controlled trials. <i>Clinical Rheumatology</i> , 2021 , 40, 683-692	3.9	4
13	Current and future therapeutic options for the management of gout. <i>American Journal of Therapeutics</i> , 2010 , 17, 402-17	1	9
12	Febuxostat: a novel agent for management of hyperuricemia in gout. <i>Indian Journal of Pharmaceutical Sciences</i> , 2011 , 73, 597-600	1.5	10
11	GOUT. 2009 , 1039-1046		
10	Febuxostat. <i>Hospital Pharmacy</i> , 2009 , 44, 688-699	1.1	

9 Antihyperuricemic Agents. **2013**, 1001-1013

8 Uric Acid and the Kidney. **2014**, 375-388

7 The current treatment strategy for gouty arthritis. *Sovremennaya Revmatologiya*, **2018**, 12, 70-75 0.7

6 Tumor Lysis Syndrome in the Cancer Patient. **2019**, 1-15

5 Tumor Lysis Syndrome in the Cancer Patient. **2020**, 1119-1133 1

4 Tumor Lysis Syndrome.. *Advances in Chronic Kidney Disease*, **2021**, 28, 438-446.e1 4.7 1

3 Simulation of Febuxostat Pharmacokinetics in Healthy Subjects and Patients with Impaired Kidney Function Using Physiologically Based Pharmacokinetic Modeling. *Biopharmaceutics and Drug Disposition*, 1.7

2 A drug-drug interaction study of a novel, selective urate reabsorption inhibitor SHR4640 and xanthine oxidase inhibitor febuxostat in patients with primary hyperuricemia. 0

1 Successful Treatment of Acute Uric Acid Nephropathy with Rasburicase in a Primary Central Nervous System Lymphoma Patient Showing a Dramatic Response to Methotrexate Case Report. **2022**, 11, 5548 0